![Peter García](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter García
Direttore Finanziario/CFO presso
Bluejay Therapeutics, Inc.
Profilo
Peter S.
García currently works at Moraga Biotechnology Corp., as Director and Bluejay Therapeutics, Inc., as Chief Financial Officer from 2024.
Mr. García also formerly worked at Noden Pharma USA, Inc., as Director, DURECT Corp., as Independent Director from 2021 to 2025, Amgen, Inc., as Principal, MDRNA, Inc., as Chief Financial Officer & Secretary in 2010, Lineage Cell Therapeutics, Inc., as CFO, Head-Investor & Media Relations from 2012 to 2013, Nuvelo, Inc., as Chief Financial Officer & Senior Vice President from 2001 to 2004, IntraBiotics Pharmaceuticals, Inc., as Chief Financial Officer from 1996 to 2004, Dendreon Corp., as Chief Financial Officer from 1996 to 2004, CYTYC Surgical Products, as Chief Financial Officer, Nanosys, Inc., as Chief Financial Officer from 2004 to 2008, Asterias Biotherapeutics, Inc., as Chief Financial Officer, Teradata Corp., as Principal, PDL BioPharma, Inc., as Chief Financial Officer & Vice President from 2013 to 2019, Adhera Therapeutics, Inc., as Chief Financial Officer, Secretary & IR Contact in 2011, Novacept, Inc., as Chief Financial Officer, and ALX Oncology Holdings, Inc., as Chief Financial Officer from 2021 to 2024.
Mr. García received his undergraduate degree in 1983 from Stanford University and Masters Business Admin degree in 1985 from the University of California, Los Angeles.
Posizioni attive di Peter García
| Società | Posizione | Inizio |
|---|---|---|
Moraga Biotechnology Corp. | Direttore/Membro del Consiglio | 11/05/2011 |
Bluejay Therapeutics, Inc.
 Bluejay Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics treatments for viral and liver diseases | Direttore Finanziario/CFO | 01/11/2024 |
Precedenti posizioni note di Peter García
| Società | Posizione | Fine |
|---|---|---|
| DURECT | Direttore/Membro del Consiglio | 11/09/2025 |
| ALX ONCOLOGY HOLDINGS INC. | Direttore Finanziario/CFO | 08/11/2024 |
| PDL BIOPHARMA, INC. | Direttore Finanziario/CFO | 15/08/2019 |
| LINEAGE CELL THERAPEUTICS, INC. | Direttore Finanziario/CFO | 10/05/2013 |
| ADHERA THERAPEUTICS, INC. | Direttore Finanziario/CFO | 08/09/2011 |
Formazione di Peter García
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
92
Relazioni di 1° grado
20
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 20 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
MDRNA, Inc.
 MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services Researches, develops, manufactures and commercializes nasally administered forms of pharmaceuticals | Commercial Services |
Lineage Cell Therapeutics, Inc.
 Lineage Cell Therapeutics, Inc. BiotechnologyHealth Technology Engages in research and development of therapeutic products for retinal & neurological diseases and disorders and oncology | Health Technology |
Nuvelo, Inc.
 Nuvelo, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic drugs using genomic technologies | Health Technology |
IntraBiotics Pharmaceuticals, Inc.
 IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops antibacterial and antifungal drugs | Health Technology |
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Discovers, develops and commercializes novel products for the treatment of cancer | Health Technology |
DURECT Corp.
 DURECT Corp. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for pain and chronic diseases | Health Technology |
CYTYC Surgical Products
 CYTYC Surgical Products Pharmaceuticals: MajorHealth Technology Manufactures therapeutic devices to improve the quality of women health care | Health Technology |
Nanosys, Inc.
 Nanosys, Inc. Chemicals: SpecialtyProcess Industries Develops and manufactures inorganic nanostructures and other related products | Process Industries |
Asterias Biotherapeutics, Inc.
 Asterias Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops and commercializes regenerative medicine for neurology and oncology applications | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Los Angeles
 University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Teradata Corp.
 Teradata Corp. Packaged SoftwareTechnology Services Provides cloud analytics software solutions | Technology Services |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology Operates as a pharmaceutical company that manufactures and wholesales prescription medicine products | Health Technology |
Adhera Therapeutics, Inc.
 Adhera Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes hypertensive drugs | Health Technology |
Moraga Biotechnology Corp. | |
Noden Pharma USA, Inc.
 Noden Pharma USA, Inc. Electronic Equipment/InstrumentsElectronic Technology Manufactures medical products | Electronic Technology |
ALX Oncology Holdings, Inc.
 ALX Oncology Holdings, Inc. BiotechnologyHealth Technology Operates as clinical stage immuno-oncology company, which develops therapies for cancer | Health Technology |
Bluejay Therapeutics, Inc.
Bluejay Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics treatments for viral and liver diseases | Health Technology |
Novacept, Inc. |
